Home > Name List By c > Cialis Finland

CAS No 171596-29-5 , Cialis Search by region : Finland

  • Name: Cialis
  • Synonyms: Tadanafil; ICOS 351; Ic351; IC-351; ADCIRCA; 1xoz; IC 351; 171596-29-5;Cialis;
  • CAS Registry Number:
  • Flash Point: 364.5ºC
  • Boiling Point: 679.1ºC at 760 mmHg
  • Density: 1.51 g/cm3
  • Refractive index: 1.705
  • Safety Statements: The most common side effects of tadalafil are: are headache, indigestion, flushing,back pain, muscle aches and stuffy or runny nose. These side effects reflect the ability of PDE5 inhibition to vasodilate (cause blood vessels to widen), these usually go a
  • Flash Point: 364.5ºC
  • Molecular Weight: 389.40396
  • InchiKey: WOXKDUGGOYFFRN-IIBYNOLFSA-N
  • InChI: InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)
    23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,
    1H3/t16-,21-/m1/s1
  • Molecular Formula: C22H19N3O4
  • Molecular Structure:CAS No:171596-29-5 Cialis

Related products

Select to

171596-29-5 Tadalafil

  • Tadalafil
  • Finland Kaukomarkkinat Oy [Manufacturer]
  • Tel: +358 9 5215901
  • Fax: +358 9 5212801
  • Address: Kutojantie 4 02630 Espoo Finland FINLAND ,nullFinland
Contact Supplier

Select to

1/1
References of Cialis
Title: Tadalafil
CAS Registry Number: 171596-29-5
CAS Name: (6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1￠,2￠:1,6]pyrido[3,4-b]indole-1,4-dione
Synonyms: (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-[3,4-(methylenedioxy)phenyl]pyrazino[1￠,2￠:1,6]pyrido[3,4-b]indole-1,4-dione
Manufacturers' Codes: GF-196960; IC-351
Trademarks: Cialis (Lilly)
Molecular Formula: C22H19N3O4
Molecular Weight: 389.40
Percent Composition: C 67.86%, H 4.92%, N 10.79%, O 16.43%
Literature References: Selective type 5 cGMP phosphodiesterase (PDE-5) inhibitor. Prepn: A. C. Daugan, WO 9519978 (1995 to Glaxo); eidem, US 5859006 (1999 to ICOS); and PDE-5 inhibition: idem et al., J. Med. Chem. 46, 4525, 4533 (2003). HPLC determn in plasma: C.-L. Cheng, C.-H. Chou, J. Chromatogr. B 822, 278 (2005). Clinical pharmacokinetics: S. T. Forgue et al., Br. J. Clin. Pharmacol. 61, 280 (2005). Clinical trial in erectile dysfunction: G. B. Brock et al., J. Urol. 168, 1332 (2002); in comparison with sildenafil: I. Eardley et al., BJU Int. 96, 1323 (2005). Review of pharmacology and clinical experience: H. Porst, Int. J. Impotence Res. 14, Suppl. 1, S57-S64 (2002); in comparison with other phosphodiesterase inhibitors: S. A. Doggrell, Expert Opin. Pharmacother. 6, 75-84 (2005).
Properties: White crystals from 2-propanol, mp 302-303°. [a]D20 +71.0° (c = 1.00 in CHCl3). Very slightly sol in ethanol. Practically insol in water.
Melting point: mp 302-303°
Optical Rotation: [a]D20 +71.0°
Therap-Cat: In treatment of male erectile dysfunction.
Keywords: Impotence Therapy; Phosphodiesterase Inhibitor.